Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Clinical Trials topic
No spam. Unsubscribe anytime.
Committee hears detailed questions about proposed state role in FDA-authorized ibogaine trials; bill rolled
Summary
HB 2075 would create a council and framework for Tennessee participation in FDA-authorized clinical research on ibogaine and similar agents; members questioned intellectual-property, commercialization, and who would own/benefit from any returns on a proposed multi-state investment; sponsors asked to roll the bill for further work.
Sponsor introduced the Helping Open Pathways to Effective Treatment Act (HB 2075), saying it would "create structured, medically supervised pathway for Tennessee institutions to participate in FDA authorized clinical... ibogaine for opioid use disorder, PTSD, traumatic brain injury, and other indications" under INDs, with safety requirements and a state council to oversee participation. The bill drew sustained questioning about commercialization and intellectual-property ownership if states make a capital investment.
Guests answering questions included Alex West (retired Navy SEAL and associate mental-health therapist), who said the state would receive a portion of any revenue in the Texas model, and Ricky Harris (CEO, Tennessee Voices), who said the bill as drafted did not itself attach state funding and that 2% of IP revenue was discussed as a mechanism to reinvest in mental-health services. Members expressed concern about becoming de facto business partners in biotech and asked for greater clarity; at the sponsor's request the bill was rolled to a later calendar.
